Keywords: Novartis, Tekturna, Hypertension, Label, USA, FDA, Gilenya, Multiple sclerosis, Alisporivir, Hepatitis C

Novartis makes Tekturna label change, updates on Gilenya and stops alisporivir trial

Article | 20 April 2012

Print This

In a day of mixed news for the Swiss drug major, Novartis (NOVN: VX) said yesterday that it has updated ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in